Fluvoxamine treatment of obsessive-compulsive disorder.
Sixteen outpatients who met DSM-III criteria for obsessive-compulsive disorder completed a 20-week double-blind, crossover trial with fluvoxamine and placebo. Thirteen (81%) improved with fluvoxamine, while three (19%) improved with placebo. Fluvoxamine treatment was associated with significant improvement on measures of obsessive-compulsive symptoms, anxiety, and depression. Depressed subjects' improvement on obsessive-compulsive measures correlated with improvement in symptoms of depression. Nondepressed subjects also showed improvement on measures of obsessive-compulsive symptoms. In this trial, fluvoxamine was an effective and safe treatment for obsessive-compulsive disorder.
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D001008:Anxiety Disorders / Q000175:diagnosis / Q000523:psychology; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000175:diagnosis / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010091:Oximes / Q000627:therapeutic use*; D010555:Personality Inventory; D010919:Placebos; D011569:Psychiatric Status Rating Scales
D010091:Oximes; D010919:Placebos; D016666:Fluvoxamine